Abstracts Archive - Page 414 of 2605 - ACR Meeting Abstracts

Abstract Number: 1576 • ACR Convergence 2023
Application of the 2022 ACR/EULAR Criteria for Takayasu Arteritis to Previously Diagnosed Patients Based on the 1990 ACR Criteria
Jang Woo Ha¹, Sung Soo Ahn², Jason Jungsik Song², Yong-Beom Park² and Sang-Won Lee³, ¹Yonsei University College of Medicine, Seodaemun-gu, Seoul, South Korea, ²Yonsei University College of Medicine, Seoul, South Korea, ³Yonsei University College of Medicine, Seoul, South Korea
Background/Purpose: Recently, a joint group of the American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR) proposed new criteria for…
Abstract Number: 1776 • ACR Convergence 2023
Macrophage Migration Inhibitory Factor May Help Maintain Tight Junctions in the Gut by Enhancing Occludin Expression
Shaghayegh Foroozan¹ and Nigil Haroon², ¹University Health Network/University of Toronto, Toronto, ON, Canada, ²University of Toronto, University Health Network, Schroeder Arthritis Institute, Department of Medicine/Rheumatology, Toronto, ON, Canada
Background/Purpose: Axial Spondyloarthritis (AxSpA) is a chronic inflammatory disease with multifactorial origins, primarily affecting the musculoskeletal system. Gut inflammation is seen in the majority of…
Abstract Number: 1761 • ACR Convergence 2023
JAK/STAT Inhibition Modifies the Innate Lymphoid Cells 1 Immune Response in Patients with Rheumatoid Arthritis
Lidia La Barbera¹, Marianna Lo Pizzo¹, Chiara Rizzo¹, Leila Mohammadnezhad¹, federica Camarda¹, Francesco Ciccia² and Giuliana Guggino¹, ¹University of Palermo, Palermo, Italy, ²University of Campania - Luigi Vanvitelli, Naples, Italy
Background/Purpose: Recent evidence suggests that innate lymphoid cells (ILCs) might be involved in rheumatoid arthritis (RA) pathogenesis and individuals at risk of RA exhibited an…
Abstract Number: 1775 • ACR Convergence 2023
The Peptidyl Arginine Deiminase Inhibitor BB-CLA Decreases the Inflammatory and Fibrotic Responses in Macrophages and Rheumatoid Arthritis Synovial Fibroblasts Exposed to Fibrinogen Modified with Malondialdehyde-Acetaldehyde Adduct and Citrulline
Jack Mordeson¹, Nozima Aripova¹, Michael Duryee¹, James O'Dell¹, Bryant England¹, Daniel Anderson¹, Ted R Mikuls² and Geoffrey Thiele¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Peptide citrullination and adduction with malondialdehyde-acetaldehyde adduct (MAA) are post-translational modifications involved in the pathogenesis of rheumatoid arthritis (RA). Anti-cyclic-citrullinated peptide antibodies are >90%…
Abstract Number: 1779 • ACR Convergence 2023
A Novel Inhibitory Pathway of Synovial Inflammation Exerted by Glucocorticoids and TNF Inhibitors Through LAG-3 Up-Regulation
Smadar Gertel¹, Victoria Furer¹, Ari Polachek¹ and Ori Elkayam², ¹Tel Aviv Sourasky Medical center, Tel Aviv, Israel, ²Tel Aviv Medical Center, Tel Aviv, Israel
Background/Purpose: Psoriatic arthritis (PsA) is a chronic immune-mediated condition that results in systemic musculoskeletal (MSK) inflammation, including peripheral synovitis, enthesitis and axial involvement. Glucocorticoids (GCs)…
Abstract Number: 1782 • ACR Convergence 2023
The Stromal-cell Derived Cytokine interleukin-17D Attenuates Joint Inflammation
Jia (Sijia) Chen¹, Catherine Manning¹, Nataliya Yeremenko², Jae-Hyuck Shim³, Daniel Montoro⁴, Dominique Baeten⁵ and Ellen Gravallese⁶, ¹Brigham and Women's Hospital, Boston, MA, ²Amsterdam University Medical Centers, Amsterdam, Netherlands, ³University of Massachusetts Chan Medical School, Worcester, MA, ⁴TenSixty Biosciences, Boston, MA, ⁵UCB Pharma, Slough, United Kingdom, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: The interleukin-17 (IL-17) family of cytokines consists of 6 evolutionarily conserved cytokines, IL-17A-F. Of these, IL-17A, B, C, and F play diverse roles in…
Abstract Number: 1777 • ACR Convergence 2023
The Effect of the Inflamed Joint Microenvironment on Endothelial Cell Function
Aenea Brugman¹, Órla Tynan², Dumitru Anton³, Carl Orr⁴, Viviana Marzaioli⁵, Douglas Veale⁶ and Ursula Fearon⁷, ¹Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin; EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, ²Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, ³Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, ⁴Saint Vincent's University Hospital, Dublin, Ireland, ⁵Trinity College Dublin and University College Dublin, Dublin, Ireland, ⁶St.Vincent's University Hosp, Dublin, Ireland, ⁷Trinity College Dublin, Dublin, Ireland
Background/Purpose: While common pathogenic mechanisms exist between PsA and RA, distinct vascular morphology has been observed, with PsA displaying a tortuous, dilated, irregular shaped morphology…
Abstract Number: 1755 • ACR Convergence 2023
Unique Pattern of Cadherin 6 Localization in Fibroblast-Like Synoviocytes
Camilla R. L. Machado¹, David Boyle¹, Narayanan B. Perumal², Robert J. Benschop³ and Gary Firestein¹, ¹University of California San Diego, San Diego, CA, ²Eli Lilly and Company, San Diego, CA, ³Eli Lilly and Company, Indianapolis, IN
Background/Purpose: The synovial lining of rheumatoid arthritis (RA) is formed by a network of fibroblast-like synoviocytes (FLS). Cadherins are type I transmembrane proteins and participate…
Abstract Number: 1780 • ACR Convergence 2023
Biomarkers Predicting Structural Progression of Axial Spondyloarthritis: A Pilot Study
Jiri Baloun¹, Kristyna Bubova¹, Aneta Pekacova², Lucia Ondrejcakova³, Vladimir Cervenak⁴, Monika Gregova⁵, Sarka Forejtova⁵, Jana Horinkova¹, Jindriska Gatterova⁶, Michal Tomcik⁷, Jiri Vencovsky⁷, Karel Pavelka⁸ and Ladislav Senolt⁹, ¹Institute of Rheumatology, Prague, Czech Republic, ²First faculty of medicine, Charles University, Prague, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴Department of Medical Imaging, St Anne's University Hospital, and Faculty of Medicine, Masaryk University, Brno, Czech Republic, ⁵Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Prague, Czech Republic, ⁶Rheumatology Institute, Prague, Czech Republic, ⁷Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁸Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic, ⁹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Praha, Czech Republic
Background/Purpose: Axial spondyloarthritis (AxSpA) is a frequent inflammatory disease with a significant impact on a patient's quality of life. Therefore, early diagnosis and recognition of…
Abstract Number: 1763 • ACR Convergence 2023
Asthma Severity Is Associated Increased Serum Anti-cyclic Antibody Level at Baseline and in Increase During Longitudinal Follow-up
Drayton Rorah¹, Linh Ngo², Mario Castro², Kristen Demoruelle³ and Scott Matson⁴, ¹University of Kansas Medical Center, Kansas City, KS, ²University of Kansas School of Medicine, Kansas City, KS, ³University of Colorado Anschutz Medical Campus, Aurora, CO, ⁴University of Kansas School of Medicine, Kansas City, MO
Background/Purpose: The lung airways have been implicated in the pathogenesis of RA. RA-associated autoantibodies, including anti-cyclic citrullinated peptide (anti-CCP) antibodies are found to be generated…
Abstract Number: 1746 • ACR Convergence 2023
Smoking as a Risk Factor for Rheumatoid Arthritis: Exclusive Association with IgA Autoantibodies
Tineke van Wesemael¹, Anna Svärd², Annemarie Dorjee¹, Thomas Huizinga¹, René Toes¹ and Diane van der Woude¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Centre for Clinical Research Dalarna, Uppsala, Sweden
Background/Purpose: Rheumatoid arthritis (RA) is characterized by autoantibodies to anti-modified protein autoantibodies (AMPAs) like anti-citrullinated protein antibodies (ACPA) and anti-acetylated protein antibodies (AAPA). Smoking is…
Abstract Number: 1764 • ACR Convergence 2023
Antibody Responses to Citrullinated Type II Collagen and Vimentin Modified with Malondialdehyde-Acetaldehyde Differ in Rheumatoid Arthritis and Rheumatoid Arthritis-Interstitial Lung Disease
Breanna Butler¹, Jill Poole¹, Michael Duryee¹, Nozima Aripova¹, Carlos Hunter¹, Bridget Kramer¹, James O'Dell¹, Geoffrey Thiele¹, Bryant England¹ and Ted R Mikuls², ¹University of Nebraska Medical Center, Omaha, NE, ²Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Interstitial lung disease (ILD) causes significant complications and mortality in patients with rheumatoid arthritis (RA). We have previously shown that patients with RA-ILD had…
Abstract Number: 1750 • ACR Convergence 2023
Dysregulated NUB1 and Neddylation Enhances Rheumatoid Arthritis Fibroblast-Like Synoviocyte Inflammatory Responses
Sho Sendo¹, Camilla R. L. Machado², Robert Benschop³, Narayanan B. Perumal⁴, Eunice Choi⁵, David Boyle⁵, Wei Wang⁵ and Gary Firestein², ¹Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²University of California San Diego, San Diego, CA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Eli Lilly and Company, San Diego, CA, ⁵University of California San Diego, La Jolla, CA
Background/Purpose: Fibroblast-like synoviocytes (FLS) contribute to the pathogenesis of rheumatoid arthritis (RA), especially cartilage damage and cytokine production. These cells display an aggressive phenotype in…
Abstract Number: 1179 • ACR Convergence 2023
Rituximab in the Treatment of Interstitial Lung Disease Associated with the Antisynthetase Syndrome
Javier Narvaez¹, Elena Cañadillas-Sanchez², Ivan Castellvi³, Juan José Alegre⁴, Paola Vidal-Montal⁵ and Joan Miquel Nolla⁵, ¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²Department of Rheumatology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ³Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Sant Just Desvern, Spain, ⁴Department of Rheumatology, Hospital Universitario Dr Peset, Valencia, Spain, ⁵Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: To assess the real-world, long-term effectiveness of rituximab (RTX) as a rescue therapy in patients with antisynthetase syndrome and interstitial lung disease (ASS-ILD). Methods:…
Abstract Number: 1758 • ACR Convergence 2023
Identification of Circulating Autoantibodies Associated with ACPA Status in Early Rheumatoid Arthritis
Lucía Lourido¹, Vijay Joshua², Monika Hansson³, Ronald Sjöberg⁴, Elisa Pin⁴, Cristina Ruiz-Romero⁵, Peter Nilsson⁴, Lars Klareskog² and Francisco J. Blanco⁶, ¹Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, Spain, ²Karolinska Institutet, Stockholm, Sweden, ³Division for Rheumatology, Department of Medicine (Solna) Karolinska Institutet, Stockholm, Sweden, ⁴Department of Protein Science, SciLifelab, KTH Royal Institute of Technology, Stockholm, Sweden, ⁵1) Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, España. 4) Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN). Av. Monforte de Lemos, 3-5. Pabellón 11,28029, Madrid, Spain, ⁶Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain
Background/Purpose: Rheumatoid arthritis (RA) is associated with the presence of autoantibodies being the anti-citrullinated protein antibodies (ACPAs) the hallmark as they are present in almost…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].